Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655956 | 0.90 | ROCK2 (0.30) | ROCK2 | |
| Trifluoroacetic Acid SCHEMBL6794145 | 0.90 | HTR5A (0.44) | HTR5AROCK2SCD5FAAHFLT1 | |
| SCHEMBL4259042 | 0.89 | HTR5A (0.33) | HTR5AROCK2 | |
| SCHEMBL4257280 | 0.89 | TRPV1 (0.34) | ROCK2FLT1KDR | |
| SCHEMBL6792403 | 0.88 | ROCK2 (0.35) | ROCK2 | |
| SCHEMBL4267034 | 0.88 | ROCK2 (0.32) | HTR5AROCK2 | |
| SCHEMBL4257197 | 0.88 | TRPV1 (0.33) | — | |
| SCHEMBL4262275 | 0.88 | FLT3 (0.35) | HTR5AFLT1KDR | |
| SCHEMBL4259036 | 0.87 | KCNK3 (0.36) | ROCK2SLC13A5 | |
| SCHEMBL4262249 | 0.87 | MCHR1 (0.34) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | HTR5A 2230/4885ROCK2 317/4885SCD5 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.